Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Relapsed or Refractory DLBCL
NCT00918463Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2009
- Primary completion
- Dec 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Weill Cornell Medicine. Started Jun 2009; status: terminated.
02
Drugs
dasatinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00918463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00918463.